f13640
Small moleculeexperimental
Befiradol is an experimental drug being studied for the treatment of levodopa-induced dyskinesia. It is a potent and selective 5-HT1A receptor full agonist. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2017 (NCT03347331)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HTR1A agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBefiradol ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03347331 | Early Phase 1 (Phase 1) | Dec 1, 2017 | University of Lyon |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1